Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis

Documenti analoghi

• Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model
  di: Owen David, et al.
  Pubblicazione: (2011-08-01)
• Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model
  di: Sivak, Olena, et al.
  Pubblicazione: (2011)
• A Novel Tropically Stable Oral Amphotericin B Formulation (iCo-010) Exhibits Efficacy against Visceral Leishmaniasis in a Murine Model
  di: Wasan, Ellen K., et al.
  Pubblicazione: (2010)
• In vitro cytotoxicity of two novel oral formulations of Amphotericin B (iCo-009 and iCo-010) against Candida albicans, human monocytic and kidney cell lines
  di: Leon, Carlos G, et al.
  Pubblicazione: (2011)
• Safety, Tolerability, and Pharmacokinetics of a Novel Oral Amphotericin B Formulation (iCo-019) following Single-Dose Administration to Healthy Human Subjects: an Alternative Approach to Parenteral Amphotericin B Administration
  di: Hnik, Peter, et al.
  Pubblicazione: (2020)